In 2005, the oral iron chelator deferasirox was approved by the FDA for clinical use as a first-
line therapy for blood-transfusion-related iron overload. Nephrotoxicity is the most serious …

Objective A meta-analysis was conducted to investigate the efficacy and safety of three main
iron chelators, namely, deferoxamine (DFO), deferiprone (DFP) and deferasirox (DFX) for …

There are few papers on the combination therapy of deferiprone (DFP) and deferasirox
(DFX) in iron-overloaded patients with transfusion-dependent β-thalassemia major (β-TM). A …

Regulatory policies on drugs have a major impact on patient safety and survival. Some
pharmaceutical companies employ all possible methods to achieve maximum sales in …

Objectives Iron overload is a common complication experienced by transfusion-dependent
children with hemoglobin disorders. Chelators such as deferasirox (DFX) and deferiprone …

Background: Considering the necessity of permanent use of iron chelating agents in patients
with thalassemia and the difficulty of using injectable drugs such as desferal, has given a …

Background: Beta-thalassemia major patients typically require chronic transfusion and iron-
chelating agents to reduce serum iron overload. Osveral® is an available Iranian brand …

Background: The health care industry is witnessing an increasing trend in the use of generic
medicines because of their presumed low cost compared with innovator medicines. The aim …

Background: Iron chelators are an important part of management of patients with
thalassemia. It is prudent to compare efficacy of different iron chelators in treatment of iron …

Background: Iron extra load is an anticipated and lethal consequence of chronic blood
transfusion in major beta-thalassemia patients; therefore it is necessary to use an efficient …